Precision's Messerschmidt Discusses New Myeloma Therapies in Managed Healthcare Executive


In the current edition of Managed Healthcare Executive, Precision Oncology’s chief medical officer Dr. Gerry Messerschmidt comments on the unprecedented pace of outcomes improvements. “New therapies in myeloma are being approved and brought into investigation at an ever-increasing rate,” he notes.

To read the complete article, please click here.